Positioning time in range in diabetes management

被引:130
作者
Advani, Andrew [1 ,2 ]
机构
[1] St Michaels Hosp, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1T8, Canada
[2] St Michaels Hosp, Li Ka Shing Knowledge Inst, 209 Victoria St, Toronto, ON M5B 1T8, Canada
基金
加拿大健康研究院;
关键词
CGM; Diabetes complications; HbA(1c); Hyperglycaemia; Hypoglycaemia; Review; Time below range; Time in range; GLUCOSE-SENSING TECHNOLOGY; HEMOGLOBIN GLYCATION INDEX; DAILY INSULIN INJECTIONS; GLYCEMIC VARIABILITY; TYPE-1; ASSOCIATION; COMPLICATIONS; HYPOGLYCEMIA; MULTICENTER; METRICS;
D O I
10.1007/s00125-019-05027-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent upswings in the use of continuous glucose monitoring (CGM) technologies have given people with diabetes and healthcare professionals unprecedented access to a range of new indicators of glucose control. Some of these metrics are useful research tools and others have been welcomed by patient groups for providing insights into the quality of glucose control not captured by conventional laboratory testing. Among the latter, time in range (TIR) is an intuitive metric that denotes the proportion of time that a person's glucose level is within a desired target range (usually 3.9-10.0 mmol/l [3.5-7.8 mmol/l in pregnancy]). For individuals choosing to use CGM technology, TIR is now often part of the expected conversation between patient and healthcare professional, and consensus recommendations have recently been produced to facilitate the adoption of standardised TIR targets. At a regulatory level, emerging evidence linking TIR to risk of complications may see TIR being more widely accepted as a valid endpoint in future clinical trials. However, given the skewed distribution of possible glucose values outside of the target range, TIR (on its own) is a poor indicator of the frequency or severity of hypoglycaemia. Here, the state-of-the-art linking TIR with complications risk in diabetes and the inverse association between TIR and HbA(1c) are reviewed. Moreover, the importance of including the amount and severity of time below range (TBR) in any discussions around TIR and, by inference, time above range (TAR) is discussed. This review also summarises recent guidance in setting 'time in ranges' goals for individuals with diabetes who wish to make use of these metrics. For most people with type 1 or type 2 diabetes, a TIR >70%, a TBR <3.9 mmol/l of <4%, and a TBR <3.0 mmol/l of <1% are recommended targets, with less stringent targets for older or high-risk individuals and for those under 25 years of age. As always though, glycaemic targets should be individualised and rarely is that more applicable than in the personal use of CGM and the data it provides.
引用
收藏
页码:242 / 252
页数:11
相关论文
共 64 条
[1]   Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes [J].
Aberer, Felix ;
Hajnsek, Martin ;
Rumpler, Markus ;
Zenz, Sabine ;
Baumann, Petra M. ;
Elsayed, Hesham ;
Puffing, Adelheid ;
Treiber, Gerlies ;
Pieber, Thomas R. ;
Sourij, Harald ;
Mader, Julia K. .
DIABETES OBESITY & METABOLISM, 2017, 19 (07) :1051-1055
[2]   FreeStyle Libre: contact irritation versus contact allergy [J].
Aerts, Olivier ;
Herman, Anne ;
Bruze, Magnus ;
Goossens, An ;
Mowitz, Martin .
LANCET, 2017, 390 (10103) :1644-1644
[3]   Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange [J].
Agiostratidou, Gina ;
Anhalt, Henry ;
Ball, Dana ;
Blonde, Lawrence ;
Gourgari, Evgenia ;
Harriman, Karen N. ;
Kowalski, Aaron J. ;
Madden, Paul ;
McAuliffe-Fogarty, Alicia H. ;
McElwee-Malloy, Molly ;
Peters, Anne ;
Raman, Sripriya ;
Reifschneider, Kent ;
Rubin, Karen ;
Weinzimer, Stuart A. .
DIABETES CARE, 2017, 40 (12) :1622-1630
[4]   Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice [J].
Ajjan, Ramzi A. ;
Cummings, Michael H. ;
Jennings, Peter ;
Leelarathna, Lalantha ;
Rayman, Gerry ;
Wilmot, Emma G. .
DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (03) :175-184
[5]   Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes [J].
Amiel, Stephanie A. ;
Aschner, Pablo ;
Childs, Belinda ;
Cryer, Philip E. ;
de Galan, Bastiaan E. ;
Heller, Simon R. ;
Frier, Brian M. ;
Gonder-Frederick, Linda ;
Jones, Timothy ;
Khunti, Kamlesh ;
Leiter, Lawrence A. ;
McCrimmon, Rory J. ;
Luo, Yingying ;
Seaquist, Elizabeth R. ;
Vigersky, Robert ;
Zoungas, Sophia .
DIABETOLOGIA, 2017, 60 (01) :3-6
[6]  
[Anonymous], 2018, DIABETES CARE S1
[7]   Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range [J].
Battelino, Tadej ;
Danne, Thomas ;
Bergenstal, Richard M. ;
Amiel, Stephanie A. ;
Beck, Roy ;
Biester, Torben ;
Bosi, Emanuele ;
Buckingham, Bruce A. ;
Cefalu, William T. ;
Close, Kelly L. ;
Cobelli, Claudio ;
Dassau, Eyal ;
DeVries, J. Hans ;
Donaghue, Kim C. ;
Dovc, Klemen ;
Doyle, Francis J. ;
Garg, Satish ;
Grunberger, George ;
Heller, Simon ;
Heinemann, Lutz ;
Hirsch, Irl B. ;
Hovorka, Roman ;
Jia, Weiping ;
Kordonouri, Olga ;
Kovatchev, Boris ;
Kowalski, Aaron ;
Laffel, Lori ;
Levine, Brian ;
Mayorov, Alexander ;
Mathieu, Chantal ;
Murphy, Helen R. ;
Nimri, Revital ;
Norgaard, Kirsten ;
Parkin, Christopher G. ;
Renard, Eric ;
Rodbard, David ;
Saboo, Banshi ;
Schatz, Desmond ;
Stoner, Keaton ;
Urakami, Tatsuiko ;
Weinzimer, Stuart A. ;
Phillip, Moshe .
DIABETES CARE, 2019, 42 (08) :1593-1603
[8]  
Beck Roy W, 2019, J Diabetes Sci Technol, V13, P614, DOI 10.1177/1932296818822496
[9]   Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials [J].
Beck, Roy W. ;
Bergenstal, Richard M. ;
Riddlesworth, Tonya D. ;
Kollman, Craig ;
Li, Zhaomian ;
Brown, Adam S. ;
Close, Kelly L. .
DIABETES CARE, 2019, 42 (03) :400-405
[10]   Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections A Randomized Trial [J].
Beck, Roy W. ;
Riddlesworth, Tonya D. ;
Ruedy, Katrina ;
Ahmann, Andrew ;
Haller, Stacie ;
Kruger, Davida ;
McGill, Janet B. ;
Polonsky, William ;
Price, David ;
Aronoff, Stephen ;
Aronson, Ronnie ;
Toschi, Elena ;
Kollman, Craig ;
Bergenstal, Richard .
ANNALS OF INTERNAL MEDICINE, 2017, 167 (06) :365-+